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 Introduction 
PD is a neurodegenerative disease that leads to motor 
impairments such as  tremor, rigidity, slowed body 
movements (bradykinesia), unstable posture and 
difficulty in walking .
1 This disease is characterized by 
the loss of dopamine (DA)-producing neurons in the 
ventral midbrain with cell bodies in the substantia nigra 
pars compacta (SNc) that project to the striatum .
2,3 
It's motor symptoms can be treated with dopaminergic 
drugs, however, their effectiveness diminishes as the 
severity of the clinical symptoms increases due to 
progression of the underlying neurodegeneration .
4 
It has been suggested that non-dopaminergic regions 
including the serotonergic neurons of dorsal raphe 
nucleus (DRN) are involved in pathology of PD .
5,6 5-
HT projections from the DRN innervate all components 
of the basal ganglia circuitry. The striatum and output 
regions of the basal ganglia (SNr and GPm) receive a 
dense serotonergic (5-HT) input.
5 
In addition to dopamine, 5-HT also modulates the 
actions of other neurotransmitters, including GABA 
and glutamate, as well as providing feedback 
mechanisms on 5-HT neurotransmission itself via an 
action in the DRN  .
7,8  It is therefore plausible that 
serotonin plays a role in the regulation of movements 
executed by the basal ganglia .
2 
Among the subtypes of 5-HT receptors, 5-HT1A 
receptors play a particularly significant role in the 
regulation of motor activity. For example, 5-HT1A 
receptor agonists attenuate the catalepsy induced by 
raclopride and anti-psychotics such as haloperidol and 
risperidone.
9For this reason, there has been a 
substantial attention on 5-HT1A  receptors and their 
involvement in motor control .
10 In an experiment by 
Gerber and colleagues it was found that 5-HT1A 
receptor stimulation represented antiparkinsonian 
effects in 6-OHDA-lesioned rats (Gerber et al., 1988). 
We have shown previously that single dose of 
buspirone decreases haloperidol 
11  and  6-
hydroxydopamine-induced catalepsy  .
2  This effect is 
most likely caused by the increase in 5-HT1A receptor 
activation resulting in an inhibition of 5-HT release .
12 
Buspirone acts as 5-HT1A receptor partial agonist and is 
used in chronic treatment of anxiety disorders .
13,14 
Since drugs may have completely different effects in 
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th day. The effect of buspirone (0.5, 1 and 2 
mg/kg, i.p. for 10 days) was assessed in 6-OHDA-lesioned rats. Results: The results 
showed that chronic injection of buspirone (0.5, 1 and 2 mg/kg, i.p. for 10 days) 
decreased catalepsy when compared with the control group. The best anticataleptic 
effect was observed at the dose of 1 mg/kg. The catalepsy-improving effect of 
buspirone was reversed by 1-(2-methoxyphenyl)- 4-[4-(2-phthalimido) butyl]piperazine 
hydrobromide (NAN-190), 0.5 mg/kg, i.p.,as a 5-HT1A receptor antagonist. Conclusion: 
Our study indicates that chronic administration of buspirone improves catalepsy in a 6-
OHDA-induced animal model of parkinson's disease (PD). We also suggest that 
buspirone may be used as an adjuvant therapy to increase effectiveness of 
antiparkinsonian drugs. In order to prove this hypothesis, further clinical studies should 
be done.  
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acute and chronic use, thus in this study we tried to 
evaluate effect of chronic administration of buspirone 
on catalepsy induced by 6-OHDA. Furtheremore,  the 
possible involvement of 5-HT1A receptor in mediating 
of observed effects was investigated. 
 
Materials and Methods 
Chemicals 
All chemicals were obtained from Sigma Chemical Co. 
(USA) except for buspirone, which was purchased from 
Heumann Co. (Germany). Solutions were prepared 
freshly on the day of experimentation. Buspirone, and 
1-(2-methoxyphenyl)-4-[4-(2-phthalimido)  butyl] 
piperazine hydrobromide (NAN-190) were dissolved in 
physiological saline (0.9% NaCl), and 6-OHDA was 
dissolved in 0.9% saline containing 0.2% (w/v) 
ascorbic acid. 6-OHDA was injected into the central 
region of the substantia nigra pars compacta (SNc) in a 
total volume of 8 μl /rat with a constant injection rate 
of 0.2 μl /min. 
 
Animals 
The experiments were carried out on male Wistar rats 
weighing 260-300 g. Animals were housed in standard 
polypropylene cages, four per cage, under a 12:12 h 
light/dark schedule at an ambient temperature of 25 ± 
2°C and were allowed food and water ad libitum. 
Animals were acclimated to the testing conditions for 2 
days before the behavioral experiment was conducted. 
All of the procedures were carried out under the ethical 
guidelines of the Tabriz University of Medical 
Sciences. 
 
6-OHDA-induced SNc lesion 
Animals were anesthetized with an ip  injection of 
ketamine  (50 mg/kg) and xylazine (5 mg/kg). After 
they were deeply anesthetized (loss of corneal and toe 
pad reflexes), rats were mounted in a stoelting 
stereotaxic frame in the flat skull position. The scalp 
was shaved, swabbed with povidone iodine 10% and a 
central incision made to expose the skull. 6-OHDA was 
injected thorough a guide cannula (23 gauge stainless 
steel) implanted in the SNc. The coordinates for this 
site were based on the rat brain atlas [30]: 
anteroposterior (AP): –5.0 mm from the bregma; 
mediolateral (ML): –2.1 mm from the midline and 
dorsoventral (DV): –7.7 from the skull.  
Desipramine (25 mg/kg, ip) was injected 30 min before 
the intranigral injection of 6-OHDA to avoid the 
destruction of noradrenergic neurons. Then, 6-OHDA 
(8 μg/per rat in 2 μl saline with 0.2% ascorbic acid) 
was infused with an infusion pump at a constant flow 
rate  of  0.2  μl/min  into  the  left  SNc.  At  the  end  of 
infusion, the injection tube was kept implanted for an 
additional 2 min and then was slowly retracted. Sham-
operated animals were submitted to the same procedure 
but  2  μl  vehicle  (0.9% saline containing 0.2% (w/v) 
ascorbic acid) of 6-OHDA was infused into the SNc. 
 
Catalepsy test 
Catalepsy was measured by using a standard bar test. In 
this method, forepaws of rats were placed over a 9-cm-
high standard wooden bar, and the duration of retention 
of rats in this imposed posture was considered as the 
bar test elapsed time. The end point of catalepsy was 
considered to occur when both front paws were 
removed from the bar or when the animal moved its 
head in an exploratory manner. The cut-off time of the 
test was 720 s. This test was carried out 5, 60, 120 and 
180 min after drug administration. All observations 
were made between 9 a.m. and 4 p.m. 
After a three-week recovery period, only the rats that 
were markedly immobilized in the bar test were 
subjected to further experimentation. Then, 
parkinsonian rats were divided randomly into equal 
groups and received once daily (9 a.m.) injections of 
buspirone, a 5-HT1A receptor partial agonist (0.5,1 and2 
mg/kg, ip) for 10 days. NAN-190, as a 5-HT1A receptor 
antagonist, was injected (0.5 mg/kg, ip) concomitantly 
with the effective dose of buspirone. 
 
Statistical analysis 
Statistical analysis of each data set was calculated by 
use of SPSS software (version 16.0). Data were 
expressed as the mean+SEM, and were analyzed by 
one-way ANOVA in each experiment. In the case of 
significant variation (p<0.05), the values were 
compared by Tukey test.  
 
Results 
Catalepsy induced by 6-OHDA 
Rats were divided into three groups: normal, sham 
operated (receiving 2 μl  vehicle)  and  6-OHDA (8 
μg/2μl/rat)-injected  rats. Drugs and vehicle were 
injected into the SNc through the implanted guide 
cannula. As shown in Figure 1, 6-OHDA was able to 
induce significant (p <  0.05 and 0.01) catalepsy in 
comparison with both normal and sham-operated  rats 
(Figure 1). 
 
Figure 1. The bar test results of control, sham-operated and 6-
OHDA (8 μg/2 μl/rat)- lesioned rats. Each bar represents the 
mean ± SEM of elapsed time (s); n = 8 rats for each group;      
* p <0.001 when compared with normal and sham-operated 
groups.(Cont.=control)  
|   129 
Chronic administration of buspirone and catalepsy 
Advanced Pharmaceutical Bulletin, 2012, 2(1), 127-131  Copyright © 2012 by Tabriz University of Medical Sciences 
Effect of buspirone on 6-OHDA induced catalepsy 
Four groups of 6-OHDA-lesioned rats received saline 
or one of three different doses of buspirone (0.5, 1 and 
2mg/kg,  ip), respectively for 10 days. The results 
indicated that buspirone attenuated the severity of 6-
OHDA induced catalepsy (p < 0.05) (Figure  2). 
 
 
Figure  2.  The bar test results of 6-OHDA  (8  μg/2  μl/rat)-
lesioned rats treated with Buspirone (0.5,1 and 2mg/kg,ip for 
10 days). Each bar represents the mean ± SEM of catalepsy 
time (s);      n = 8 rats for each group; * p < 0.001 when 
compared with 6-OHDA-lesioned rats. (Bus=Buspirone) 
Effect of NAN-190 co-injection with buspirone on 6-
OHDA-induced catalepsy 
Three groups of 6-OHDA-lesioned animals 
respectively received saline, buspirone (1 mg/kg, ip) or 
buspirone  (1 mg/kg, ip) with NAN-190  (0.5μmg/rat, 
ip). The results showed that the catalepsy-ameliorating 
effect of buspirone was abolished (p < 0.05) by NAN-
190 (Figure 3). 
 
 
Figure  3.  The bar test results from the co-administration of 
NAN-190 (0.5 mg/kg,  ip) with buspirone (1mg/kg, ip for 10 
days) in 6-OHDA-lesioned rats. Each bar represents the mean 
± SEM of catalepsy time (s); n = 8 rats for each group,a, p < 
0.001 when compared with 6-OHDA-lesioned rats; b, p < 0.001 
when compared with 6-OHDA-lesioned rats co-treated with 
NAN-190(0.5mg/kg,ip) and buspirone (1 mg/kg,ip) 
.Cont.=control, Bus.=buspirone 
 
Discussion 
In our previous study the potential anticataleptic effects 
of  5-HT1A  agonists in 6-OHDA-lesioned rats  were 
investigated in single dose administrations .
2 Since in 
clinic drugs are used chronically, therefore in this study 
we studied the potential anticataleptic effects of chronic 
administration of buspirone in 6-OHDA-lesioned rats. 
Our results showed intra-SNc injection of 6-OHDA 
induced catalepsy when assessed by the bar test. This is 
a standard test frequently used for evaluating catalepsy 
induced by 6-OHDA and neuroleptic drugs in rodents 
.
2,11,15  According to the results, buspirone, a partial 
agonist of 5-HT1A receptors, improved catalepsy in 6-
OHDA-lesioned rats. This confirms our previous study 
reporting a promising role for 5-HT1A  agonists in 
decreasing the motor disorders associated with PD.
2,11 
5-Hydroxytryptamine 1A (5-HT1A) receptors are 
widely distributed throughout the basal ganglia. They 
are located on dorsal raphe neurons with efferents to 
the striatum and on cortical neurons that  send 
glutamatergic projections to the basal ganglia 
.
12.Stimulation of 5-HT1A  receptors in these regions 
leads to dopamine release 
16    via the inhibition of 
adenyl cyclase and the opening of potassium channels 
.
17 It seems that 5-HT1A receptor agonists can reduce 
serotonin synthesis and release  by activation of 
presynaptic, somatodendritic autoreceptors on raphe 
serotonergic cell bodies .
10 A potential role of 5-HT1A 
agonists in the enhancement of motor activity was 
suggested because stimulation of somatodendritic 5-
HT1A  receptors by a selective agonist such as 8-
hydroxy-2-(di-n-propylamino)  tetralin (8-OH-DPAT) 
inhibited synthesis of 5-HT to decrease its release from 
the nerve endings .
18 
The mechanism by which buspirone exerts an 
anticataleptic effect in 6-OHDA-lesioned  rats was 
studied by using 5-HT1A  receptor antagonists. In 
addition to 5-HT1A receptors, buspirone has D2 and α2-
adrenoceptor blocking effects .
14,19 Thus, it seems that 
D2 and α2 receptors may be involved in the observed 
effects of buspirone. In this study the catalepsy-
improving effect of buspirone was reversed by NAN-
190, a 5-HT1A receptor antagonist. This confirms the 
involvement of 5-HT1A receptors in the observed effect 
of buspirone. According to the obtained results, we 
suggest that chronic administration  of  buspirone 
alleviates catalepsy in 6-OHDA-lesioned rats by acting 
on 5-HT1A receptors in the SNc, and may it be used as a 
potential adjuvant drug together with routinely used 
antiparkinsonian drugs. 
We investigated anticataleptic effect of different 
chronic doses of buspirone. The results showed that 
anticataleptic effect of buspirone at dose of 1 mg/kg 
was more than doses of 0.5 and 2. On the other hand, 
the anticataleptic effect of buspirone was attenuated by 
increasing the dose. Studies show that buspirone exerts 
dose-dependent opposite effects on the function of the 
nigrostriatal dopaminergic neurons so that at high 
doses, it acts as an antagonist on  D2  receptors  .
13 
Furthermore, the affinity of buspirone on 5-HT1A 
receprots is higher than D2 receptors  .
20,21,22  Thus the 
possible involvement of D2  receptors should not be 
neglected at it's high doses.  
In conclusion our data suggest that chronic 
administration of buspirone improves catalepsy in 6-
OHDA-lesioned rats. Inaddition we suggest that it may 
be used as an adjuvant therapy for improving effects of  
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antiparkinson drugs. However, further clinical 
investigations should be carried out to prove it.  
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